

Serial No. 09/960,449

**RESPONSE TO OFFICE ACTION**

**Amendments to the Claims**

Claims 1-4, 8-11, 13-17, 21-23, 25, and 27-29 are pending in the application. This listing of claims will replace all previous listings of claims in this application. No claims have been amended in this Response.

**Listing of Claims**

1. (previously presented) A hydrogel wound dressing formed by spray delivery of a liquid composition to the wound, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and the macromers crosslink to form a hydrogel *in situ* on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups, and wherein the composition includes a crosslinking initiator that is not bound to a macromer or another polymer.

2. (original) The wound dressing of claim 1, wherein the hydrogel is degradable.

3. (original) The wound dressing of claim 1, wherein the composition is delivered via an aerosol delivery device.

4. (original) The wound dressing of claim 1, wherein the composition is delivered via a pump spray delivery device.

5-7. (cancelled)

8. (original) The wound dressing of claim 1, wherein the composition further contains one or more additives selected from the group consisting of preservatives, biologically active agents, defoamers, wettings agents, leveling agents, hydrating agents, thickeners, fillers, and absorbents.

9. (previously presented) The wound dressing of claim 8, wherein the active agent is selected from the group consisting of growth factors, nitric oxide, antibiotics, anti-inflammatories, analgesics, blood coagulants, and enzymes.

10. (original) The wound dressing of claim 8, wherein the active agent is one which delivers NO to the wound.

11. (original) The wound dressing of claim 1, wherein the dressing debrides the wound when it is removed.

12. (cancelled)

Serial No. 09/960,449

**RESPONSE TO OFFICE ACTION**

13. (previously presented) The wound dressing of claim 1, wherein the *in situ* crosslinking is in response to redox initiation.

14. (previously presented) A method of forming a hydrogel wound dressing, comprising the step of applying a composition to a wound via spray, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and the macromers crosslink to form a hydrogel on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups and wherein the composition includes a crosslinking initiator that is not bound to a macromer or another polymer.

15. (original) The method of claim 14, wherein the hydrogel is degradable.

16. (original) The method of claim 14, wherein the composition is delivered via an aerosol delivery device.

17. (original) The method of claim 14, wherein the composition is delivered via a pump spray delivery device.

18- 20. (cancelled)

21. (original) The method of claim 14, wherein the composition further contains one or more additives selected from the group consisting of preservatives, biologically active agents, defoamers, wetting agents, leveling agents, hydrating agents, thickeners, fillers, and absorbents.

22. (previously presented) The method of claim 21, wherein the active agent is selected from the group consisting of growth factors, nitric oxide, antibiotics, anti-inflammatories, analgesics, blood coagulants, and enzymes.

23. (original) The method of claim 21, wherein the active agent is one which delivers NO.

24. (cancelled)

25. (previously presented) The method of claim 14, wherein the *in situ* crosslinking is in response to redox initiation.

26. (cancelled)

27. (previously presented) The wound dressing of claim 1, wherein the crosslinking initiator is a redox couple in solution.

28. (previously presented) The method of claim 14, wherein the crosslinking initiator is a redox couple in solution.

BIOCURE 161

Serial No. 09/960,449

**RESPONSE TO OFFICE ACTION**

29. (previously presented) A hydrogel wound dressing formed by spray delivery of a liquid composition to the wound, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and the macromers crosslink to form a hydrogel *in situ* on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups, and wherein the composition includes an unbound crosslinking initiator in solution.